机译:FLIGHT1和FLIGHT2:慢性阻塞性肺疾病患者QVA149(茚达特罗/格隆溴铵)及其单组分和安慰剂的疗效和安全性
Geisel School of Medicine at Dartmouth, Hanover, New Hampshire,Valley Regional Hospital, Claremont, New Hampshire,Geisel School of Medicine at Dartmouth, Director of Respiratory Services, Valley Regional Hospital, Claremont, NH 03743;
Clinical Research Institute of Southern Oregon, Medford, Oregon;
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey;
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey;
Novartis Healthcare Pvt. Ltd., Hyderabad, India;
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey;
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey;
Novartis Pharma AG, Basel, Switzerland;
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey;
COPD; long-acting β_2-agonists; long-acting muscarinic antagonist; clinical trial; fixed-dose combination;
机译:慢性阻塞性肺病患者中茚达特罗和格隆铵(QVA149),其单组分和噻托溴铵固定剂量组合与安慰剂的合并安全性分析
机译:QVA149在慢性阻塞性肺疾病患者中显示出比茚达特罗或安慰剂更好的支气管扩张作用。
机译:茚达特罗150和300μg对包括日本在内的六个亚洲地区的慢性阻塞性肺疾病患者的疗效和安全性:一项为期12周的安慰剂对照研究。
机译:慢性阻塞性肺疾病的远程医疗随访已整合到以患者为中心的医疗团队中-对患者赋权和安全的影响
机译:DVD技术在农村地区慢性阻塞性肺疾病自我管理教育中的作用
机译:每日两次茚达特罗/格隆溴铵对中度至重度慢性阻塞性肺疾病患者健康相关的生活质量和呼吸困难的影响
机译:茚达特罗和格隆铵(QVA149),其单组分和噻托溴铵固定剂量联合使用对安慰剂与安慰剂的合并安全性分析